Drug development – Page 14

Analytical variability unexplained during regulatory data review – risk-based methodology optimization

“`html Investigating Unexplained Analytical Variability During Regulatory Data Review In pharmaceutical development, unexplained analytical variability can lead to significant challenges during regulatory data reviews. This article outlines a structured investigation…

Non-clinical toxicity findings during sponsor oversight – preventing clinical hold

Addressing Non-clinical Toxicity Findings During Sponsor Oversight to Prevent Clinical Holds In the complex landscape of drug development, non-clinical toxicity findings present significant challenges that can lead to unfavorable clinical…

Reproducibility gaps during IND-enabling studies – FDA/EMA non-clinical expectations

Addressing Reproducibility Issues in IND-Enabling Studies: A Systematic Investigation In the realm of drug development, particularly during IND-enabling studies, reproducibility gaps can signal potential pitfalls that jeopardize future regulatory submissions.…

Reproducibility gaps during program hold risk review – FDA/EMA non-clinical expectations

Addressing Reproducibility Gaps in Program Hold Risk Reviews for FDA and EMA In the pharmaceutical development landscape, particularly in preclinical studies, reproducibility gaps can greatly challenge decision-making during program hold…

GLP readiness concerns during IND-enabling studies – CAPA for study design gaps

Addressing GLP Readiness Concerns in IND-Enabling Studies: A Comprehensive CAPA Investigation The journey from drug discovery to clinical trials is fraught with challenges, not least of which are Good Laboratory…

Non-clinical toxicity findings during regulatory submission prep – how to defend preclinical package

Addressing Non-clinical Toxicity Findings During Regulatory Submission Preparation In the realm of pharmaceutical development, encountering non-clinical toxicity findings during the preparation of regulatory submissions can pose significant challenges. These findings,…

Non-clinical toxicity findings during IND-enabling studies – preventing clinical hold

Addressing Non-Clinical Toxicity Findings to Prevent Clinical Holds in IND-Enabling Studies Non-clinical toxicity findings during Investigational New Drug (IND)-enabling studies often introduce considerable risk during the drug development process. Identifying…

GLP readiness concerns during regulatory submission prep – how to defend preclinical package

Addressing GLP Readiness Issues During Regulatory Submissions The successful transition from preclinical studies to regulatory submissions hinges on thorough preparation, particularly regarding Good Laboratory Practice (GLP) readiness. Issues in this…

Reproducibility gaps during IND-enabling studies – CAPA for study design gaps

Addressing Reproducibility Challenges in IND-Enabling Studies: A Systematic Investigation The increasing complexity of drug discovery has heightened scrutiny on reproducibility within IND-enabling studies. These studies serve as foundational components, influencing…

Tag: Drug development